共 15 条
[1]
Neuroprotection in Parkinson models varies with toxin administration protocol. Anderson DW,Bradbury KA,Schneider JS. European Journal of Neuroscience . 2006
[2]
Dopamine depletion does not protect against acute1-meth-yl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in vivo. Hasbani DM. The Journal of Neuroscience . 2005
[3]
The potentiating effects of1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)on paraquat-induced neurochemical and be-havioral changes in mice. Shepherd KR. Pharmacol Biochem Behav . 2006
[4]
Neuroprotective effects of caffeine in the model of6-hydroxydopamine lesion in rats. Aguiar LM. Pharmacol Biochem Behav . 2006
[5]
Physiological neuroprotection by melatonin in a6-hydroxydo-pamine model of Parkinson’s disease. Sharma R. Brain Research . 2006
[6]
Animal models of Parkinson’s disease: An empirical comparison with the phenomenology of the disease in man[J] . M. Gerlach,P. Riederer.  Journal of Neural Transmission . 1996 (8)
[7]
Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment[J] . E Petroske,G.E Meredith,S Callen,S Totterdell,Y.-S Lau.  Neuroscience . 2001 (3)
[10]
Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Petroske E,Meredith G E,Callen S,et al. Neuroscience . 2001